As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at pharmaceuticals stocks, starting with ...

Investigators find only moderate agreement between ocular POCUS and ophthalmologist diagnoses in emergency settings for vision-threatening conditions.

DEXTENZA ® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investigators call for stricter eye protection mandates and school awareness programs to reduce the global burden of ophthalmic trauma.

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

Event-driven snapshot of Ocular Therapeutix Ocular Therapeutix (OCUL) has been drawing attention after recent share price swings, including a 6.8% decline over the past day, offset by a 14.9% gain ...

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the ...

Learn more about whether Ocular Therapeutix, Inc. or Phibro Animal Health Corporation is a better investment based on AAII's ...

Dry eye disease is linked to poor sleep quality, with shared inflammatory pathways contributing to a bidirectional relationship in patients.

Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell short of the market’s revenue expectations in Q4 CY2025, with sales falling 22.4% year on year to $13.25 million. Its ...

On Friday, BofA Securities began coverage of Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company, assigning a Buy rating ...

The latest announcement is out from Ocular Therapeutix ( (OCUL)). On December 18, 2025, Ocular Therapeutix announced it will enter a quiet period starting December 20, 2025 as it prepares for database ...